674 studies found for:    Cetuximab
Show Display Options
Rank Status Study
1 Active, not recruiting Phase 1 and 2 Study of PX-866 and Cetuximab
Conditions: Incurable Metastatic Colorectal Carcinoma;   Incurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: PX-866 and cetuximab;   Drug: Cetuximab
2 Recruiting ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: Cetuximab;   Procedure: Surgery;   Radiation: Post-surgical radiation;   Drug: Cisplatin or carboplatin
3 Completed
Has Results
Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC)
Condition: Non-Small Cell Lung Cancer (NSCLC)
Interventions: Drug: Cetuximab plus Platinum-based Doublet Chemotherapy;   Drug: Cetuximab 500 mg/m^2;   Drug: Cetuximab 250 mg/m^2
4 Active, not recruiting External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas
Condition: Brain Cancer
Intervention: Other: cetuximab in conjunction with external beam radiation therapy, followed by cetuximab and irinotecan
5 Recruiting Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Conditions: Recurrent;   Head and Neck Cancer
Interventions: Radiation: SBRT;   Drug: Cetuximab;   Drug: Docetaxel
6 Completed Cetuximab in Neoadjuvant Treatment of Non-Resectable Colorectal Liver Metastases (CELIM)
Conditions: Colorectal Cancer;   Liver Metastases
Interventions: Drug: Cetuximab;   Procedure: Liver resection;   Drug: Cetuximab and FOLFIRI;   Drug: Cetuximab and FOLFOX
7 Active, not recruiting A Trial Exploring the Efficacy of EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)
Condition: Squamous Cell Carcinoma of the Head and Neck Cancer
Interventions: Drug: Cetuximab in combination with EMD 1201081;   Drug: Cetuximab alone
8 Recruiting Regorafenib and Cetuximab in Patients With Advanced Malignancy
Condition: Advanced Cancers
Interventions: Drug: Regorafenib;   Drug: Cetuximab;   Behavioral: Questionnaire
9 Active, not recruiting Safety and Efficacy Study of mFOLFOX-6 Plus Cetuximab for 8 Cycles Followed by mFOLFOX-6 Plus Cetuximab or Single Agent Cetuximab as Maintenance Therapy in Patients With Metastatic Colorectal Cancer and WT KRAS Tumours
Condition: Metastatic Colorectal Cancer
Interventions: Drug: mFOLFOX-6 + cetuximab until disease progression or early withdrawal.;   Drug: 8 cycles of mFOLFOX-6 + cetuximab, followed by cetuximab alone until disease progression or early withdrawal.
10 Completed Docetaxel, Cetuximab and Cisplatin Followed by Radiation, Cetuximab and Cisplatin in Head and Neck Cancer
Condition: Cancer
Interventions: Drug: Docetaxel;   Drug: Cisplatin;   Drug: Cetuximab;   Procedure: Radiation Therapy
11 Completed
Has Results
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer
Condition: Head and Neck Cancer
Interventions: Biological: Cetuximab;   Drug: Carboplatin;   Drug: Paclitaxel;   Radiation: Radiation therapy
12 Recruiting Non-invasive Imaging of Cetuximab-Zr. 89 Uptake Wit PET: a Phase I Trial in Stage IV Cancer Patients
Condition: Stage IV Cancer
Intervention: Drug: Cetuximab-Zr. 89
13 Recruiting Bevacizumab, Temsirolimus, Valproic Acid, Cetuximab
Condition: Advanced Cancers
Interventions: Drug: Temsirolimus;   Drug: Bevacizumab;   Drug: Valproic Acid;   Drug: Cetuximab
14 Completed
Has Results
Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442)
Condition: Cancer of Head and Neck
Interventions: Drug: Erbitux, Paclitaxel & Carboplatin;   Radiation: Radiation
15 Recruiting Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Biological: Imprime PGG + cetuximab;   Drug: Cetuximab
16 Terminated
Has Results
Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer
Condition: Esophageal Cancer
Interventions: Drug: 5-Fluorouracil;   Drug: Oxaliplatin;   Drug: Cetuximab;   Drug: Docetaxel;   Procedure: Surgery;   Radiation: Radiotherapy
17 Not yet recruiting Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer
Conditions: Stage III Squamous Cell Carcinoma of the Hypopharynx;   Stage III Squamous Cell Carcinoma of the Larynx;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Verrucous Carcinoma of the Larynx;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Verrucous Carcinoma of the Larynx;   Tongue Cancer
Interventions: Biological: cetuximab;   Drug: cisplatin;   Radiation: external beam radiation therapy;   Other: laboratory biomarker analysis
18 Recruiting Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination
Condition: Neoplasms
Interventions: Drug: Regorafenib (Stivarga, BAY73-4506);   Drug: Cetuximab (ERBITUX)
19 Active, not recruiting Erlotinib in Combination With Cetuximab
Condition: Advanced Cancers
Interventions: Drug: Erlotinib;   Drug: Cetuximab
20 Completed Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib
Condition: Lung Adenocarcinoma
Intervention: Drug: erlotinib along with cetuximab

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years